dc.creatorDINIZ, J. B.
dc.creatorSHAVITT, R. G.
dc.creatorPEREIRA, C. A. B.
dc.creatorHOUNIE, A. G.
dc.creatorPIMENTEL, I.
dc.creatorKORAN, L. M.
dc.creatorDAINESI, S. M.
dc.creatorMIGUEL, E. C.
dc.date.accessioned2012-10-19T18:24:23Z
dc.date.accessioned2018-07-04T15:11:45Z
dc.date.available2012-10-19T18:24:23Z
dc.date.available2018-07-04T15:11:45Z
dc.date.created2012-10-19T18:24:23Z
dc.date.issued2010
dc.identifierJOURNAL OF PSYCHOPHARMACOLOGY, v.24, n.3, p.297-307, 2010
dc.identifier0269-8811
dc.identifierhttp://producao.usp.br/handle/BDPI/23118
dc.identifier10.1177/0269881108099423
dc.identifierhttp://dx.doi.org/10.1177/0269881108099423
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1619848
dc.description.abstractAfter 12 weeks of selective serotonin reuptake inhibitor (SSRI) monotherapy with inadequate response, 10 patients received clomipramine and 11 received quetiapine as augmentation agents of the SSRI. The primary outcome measure was the difference between initial and final scores of the YaleBrown Obsessive-Compulsive Scale (Y-BOCS), rated in a blinded fashion, and the score of clinical global improvement (CGI-I). Statistical analyses were performed using nonparametric tests to evaluate treatment efficacy and the difference between treatment groups. Percentile plots were constructed with YBOCS scores from the clomipramine and quetiapine groups. Considering response a >= 35% reduction in the initial Y-BOCS score plus a rating of `much improved` or `very much improved` on CGI-I, four of eleven quetiapine patients and one out of ten clomipramine patients were classified as responders. The mean final Y-BOCS score was significantly lower than baseline in the quetiapine augmentation group (P = 0.023), but not in the clomipramine augmentation group (P = 0.503). The difference between groups showed a trend towards significance only at week 4, the mean Y-BOCS score being lower for those receiving quetiapine (P = 0.052). A difference between groups was also observed at week 4 according to percentile plots. These results corroborate previous findings of quetiapine augmentation efficacy in obsessive-compulsive disorder (OCD). Clomipramine augmentation did not produce a significant reduction in Y-BOCS scores. Higher target maximum dosages might have yielded different results.
dc.languageeng
dc.publisherSAGE PUBLICATIONS LTD
dc.relationJournal of Psychopharmacology
dc.rightsCopyright SAGE PUBLICATIONS LTD
dc.rightsrestrictedAccess
dc.subjectclomipramine
dc.subjectobsessive compulsive disorder
dc.subjectpsychiatry
dc.subjectquetiapine
dc.subjectserotonin reuptake inhibitors
dc.titleQuetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución